Cytokinetics (NASDAQ: CYTK) CFO trades shares after option exercises
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
CYTOKINETICS INC EVP and CFO Sung Lee reported a mix of option exercises and share sales. On June 29, 2026, Lee exercised options to acquire a total of 3,134 shares of common stock through multiple transactions at exercise prices of $44.36 and $48.51 per share. On the same date, Lee executed an open-market sale of 3,134 shares of common stock at $85.00 per share, effectively converting option-based compensation into cash while shifting exposure from options into owned shares.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 3,134 shares ($266,390)
Net Sell
11 txns
Insider
Lee Sung
Role
EVP, Chief Financial Officer
Sold
3,134 shs ($266K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Incentive Stock Option (Right to Buy) | 188 | $0.00 | -- |
| Exercise | Non-Qualified Stock Option (Right to Buy) | 822 | $0.00 | -- |
| Exercise | Non-Qualified Stock Option (Right to Buy) | 1,113 | $0.00 | -- |
| Exercise | Incentive Stock Option (Right to Buy) | 188 | $0.00 | -- |
| Exercise | Non-Qualified Stock Option (Right to Buy) | 823 | $0.00 | -- |
| Exercise | Common Stock | 188 | $44.36 | $8K |
| Exercise | Common Stock | 822 | $44.36 | $36K |
| Exercise | Common Stock | 1,113 | $48.51 | $54K |
| Exercise | Common Stock | 188 | $44.36 | $8K |
| Exercise | Common Stock | 823 | $44.36 | $37K |
| Sale | Common Stock | 3,134 | $85.00 | $266K |
Holdings After Transaction:
Incentive Stock Option (Right to Buy) — 8,828 shares (Direct, null);
Non-Qualified Stock Option (Right to Buy) — 40,504 shares (Direct, null);
Common Stock — 63,409 shares (Direct, null)
Footnotes (1)
Key Figures
Shares sold: 3,134 shares
Sale price: $85.00 per share
Options exercised (shares): 3,134 shares
+4 more
7 metrics
Shares sold
3,134 shares
Open-market sale of common stock on June 29, 2026
Sale price
$85.00 per share
Price for 3,134 common shares sold
Options exercised (shares)
3,134 shares
Total shares acquired via option exercises (code M)
Option strike price
$44.36 per share
Exercise price on several option transactions
Option strike price
$48.51 per share
Exercise price on one option transaction
Option exercise count
5 transactions
Number of derivative exercises reported (code M)
Net buy/sell direction
net-sell of 3,134 shares
Transaction summary netBuySellDirection and netBuySellShares
Key Terms
open-market sale, Non-Qualified Stock Option (Right to Buy), Incentive Stock Option (Right to Buy), derivative exercise/conversion, +1 more
5 terms
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Non-Qualified Stock Option (Right to Buy) financial
"security_title": "Non-Qualified Stock Option (Right to Buy)""
Incentive Stock Option (Right to Buy) financial
"security_title": "Incentive Stock Option (Right to Buy)""
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
transaction_code "M" financial
"transaction_code": "M""
FAQ
What did Cytokinetics (CYTK) CFO Sung Lee report in this Form 4?
Cytokinetics CFO Sung Lee reported exercising stock options for 3,134 shares and selling 3,134 common shares. The trades reflect routine management of equity compensation, combining derivative exercises with an open-market sale at a higher market price.
What stock options did the Cytokinetics CFO exercise in this filing?
The CFO exercised options covering a total of 3,134 shares of Cytokinetics common stock. These options had exercise prices of $44.36 and $48.51 per share and were reported across several transactions on June 29, 2026.
Does this Cytokinetics Form 4 show new option exercises or just sales?
The Form 4 shows both new option exercises and a sale. Sung Lee exercised options for 3,134 shares at strike prices of $44.36 and $48.51, then sold 3,134 common shares in an open-market transaction at $85.00 per share.
Is the Cytokinetics CFO’s transaction mainly a sale or an option exercise?
The activity combines option exercises and a sale. Sung Lee exercised options to acquire 3,134 shares and then sold 3,134 shares in the open market, a common pattern for monetizing equity compensation while adjusting overall exposure.